Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

282 trials

NCT06834373
Recruiting
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Phase 2 · United States · 7 sites
Registry update: 20 Oct 2026
NCT06803693
Recruiting
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 · China · 1 site
Registry update: 8 Dec 2025
NCT06867536
Recruiting
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Phase 2 · China · 1 site
Registry update: 15 May 2026
NCT06980116
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · Spain, France, United Kingdom, Georgia, Greece, Moldova, Poland, Romania, Ukraine · 22 sites
Registry update: 13 Aug 2026
NCT06830759
Recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Not applicable · Argentina, Austria, Australia, Belgium, Bulgaria, Canada, Spain, United Kingdom, Greece, Israel, Italy, Mexico, Portugal · 73 sites
Registry update: 17 Feb 2026
NCT06830031
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 · China · 1 site
Registry update: 11 Sept 2026
NCT06854445
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Phase 2 · China · 24 sites
Registry update: 24 Mar 2025
NCT06785818
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
Not applicable · South Korea · 8 sites
Registry update: 30 Jul 2026
NCT06784167
Recruiting
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Not applicable · United States · 1 site
Registry update: 23 Sept 2026
NCT06806033
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Phase 2 · Australia, Canada, Germany, France, Italy, South Korea, United States · 52 sites
Registry update: 10 Nov 2026
Conflicting statuses (updated in the registry within the last month)
NCT07198230
Recruiting
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Not applicable · China · 1 site
Registry update: 18 Nov 2025
NCT07188077
Recruiting
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Not applicable · China · 1 site
Registry update: 18 Nov 2025
NCT06570447
Recruiting
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Phase 2 · China · 1 site
Registry update: 3 Aug 2026
NCT06832267
Recruiting
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Not applicable · China · 1 site
Registry update: 18 Feb 2025
NCT05077527
Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · United States · 7 sites
Registry update: 10 Jul 2026
NCT05990465
Recruiting
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · United States · 1 site
Registry update: 6 Aug 2026
NCT06764017
Recruiting
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Phase 2 · China · 1 site
Registry update: 19 Mar 2025
NCT06717347
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Switzerland, Chile, China, Colombia, Denmark, Spain, France, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, South Korea, Mexico, Malaysia, Netherlands, Peru, Poland, Puerto Rico, Portugal, Romania, Singapore, Thailand, Türkiye, Taiwan, Ukraine, United States, South Africa · 289 sites
Registry update: 10 Nov 2026
NCT06050694
Recruiting
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Phase 2 · Canada · 2 sites
Registry update: 24 Apr 2026
NCT06687772
Recruiting
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Phase 2 · United States · 1 site
Registry update: 28 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.